Close
Almac
Achema middle east

Merck and Tridonic Enter Into License Agreement for White LEDs

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.
- Advertisement -

Merck, a leading company for innovative and top-quality high-tech products in the healthcare, life science and performance materials sectors, announced today that it has entered into a license agreement with Tridonic Jennersdorf GmbH (Tridonic) covering silicate phosphors for use in white light LEDs.

Along with Toyoda Gosei Co. Ltd. (Japan), Leuchtstoffwerk Breitungen GmbH (Germany), and Litec GbR (Germany), Tridonic holds basic patents relating to a technology to generate white light using blue LEDs and novel yellow silicate phosphors. This combination of silicate phosphors applied to blue LED chips enable manufacturing of packaged white LEDs with high accuracy and high brightness. Primary applications include backlights for cell phones, laptops, GPS and other small displays, which account for a high share of today’s global LED market.

Latest stories

Related stories

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio

AstraZeneca has gone ahead and committed $100 million to...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Samsung Biologics to Buy US Drug Plant from GSK for $280M

On December 22, 2025, the news has been confirmed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »